Tolerability of topical NSAIDs in the elderly: Do they really convey a safety advantage?

Drugs and Aging

Volumn 9, Issue 2, 1996, Pages 101-108

  Evans, Josie M M ^a   MacDonald, Thomas M ^a,b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGING; ARTHROPATHY; ASTHMA; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CONFUSION; CONTACT DERMATITIS; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; HYPERTENSION; LIVER TOXICITY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHOTODERMATOSIS; PRIORITY JOURNAL; RASH; REVIEW; SKIN TOXICITY; TOPICAL DRUG ADMINISTRATION;

EID: 0029763761     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609020-00005     Document Type: Review

References (70)

1. Prescriptions Pricing Authority. Annual report. Newcastle upon Tyne: PPA, 1993
2. Information and Statistics Division. Scottish health statistics 1994. Edinburgh: National Health Service in Scotland, 1994
3. Porter DR, Sturrock RD. Medical management of rheumatoid arthritis. BMJ 1993; 307: 425-8
4. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions (Pt 1). BMJ 1986; 292: 614
5. Fries JF, Williams CA, Ramey D, et al. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306
6. Johnson AG, Quinn DI, Day RO. Non-steroidal anti-inflammatory drugs. Med J Aust 1995; 163: 155-8
7. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88
8. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
9. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
10. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 539-45
11. Bateman DN. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994; 343: 1051-2
12. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by non-steroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 625-32
13. Bjarnason I, Hayllar J, MacPherson AJS, et al. Side-effects of nonsteroidal anti-inflammatory drugs on the small and large intestine of humans. Gastroenterology 1993; 104: 1832-47
14. Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347-9
15. Henry DA. Gastrointestinal bleeding and non-steroidal anti-inflammatory drugs. Curr Med 1994; 3: 171-89
16. Anonymous. Rational use of NSAIDs for musculoskeletal disorders. Drug Ther Bull 1994; 32: 91-5
17. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28: 527-32
18. MacDonald TM. Selected side effects: 14. Non-steroidal anti-inflammatory drugs and renal damage. Prescr J 1994; 34: 77-80
19. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 1990; 112: 559-60
20. Whelton A, Stout RL, Spilman PS, et al. Renal effects of ibuprofen, piroxicam and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568-76
21. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-72
22. Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit: a record-linkage system for pharmacovigilance. Pharm Med 1995; 9: 165-76
23. Evans JMM, McGregor E, McMahon AD, et al. Non-steroidal anti-inflammatory drugs and hospitalisation for acute renal failure. Q J Med 1995; 88: 551-7
24. Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease - still unsettled. Ann Intern Med 1991; 115: 227-8
25. Jick H, Derby LE, Garcia-Rodriguez LA, et al. Liver disease associated with diclofenac, naproxen and piroxicam. Pharmacotherapy 1992; 12: 207-12
26. Garcia-Rodriguez LA, Gutthann SP, Walker AM, et al. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865-8
27. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med 1994; 121: 289-300
28. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994; 272: 781-6
29. Biscarini L. Anti-inflammatory analgesics and drugs used in gout. In: Dukes MNG, editor. Meyler's side-effects of drugs 12th ed. London: Elsevier, 1992: 184-6
30. International Agranulocytosis and Aplastic Anaemia Study Risks of agranulocytosis and aplastic anaemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749-57
31. Rashad S, Revell P, Hemingway A, et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; II: 519-21
32. Anti-inflammatory agents and asthma. Curr Probl 1975; 1: 2
33. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary No. 28 (September 1994). London: British Medical Association and Pharmaceutical Press, 1994
34. Stockley IH. Drug interactions. 2nd ed. Oxford: Blackwell Scientific Publications, 1991: 39-72
35. Faulkner G, Prichard P, Somerville K, et al. Aspirin and bleeding peptic ulcers in the elderly. BMJ 1988; 297: 1311-3
36. Committee on Safety of Medicines. Relative safety of non-aspirin NSAIDs. Curr Probl 1994; 20: 9-12
37. Dieppe PA, Frankel SJ, Toth B. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet 1993; 341: 353-4
38. Brandt KD, Bradley JD. Simple analgesics versus NSAIDs for osteoarthritis [letter]. Lancet 1993; 341: 770-1
39. March L, Irwig L, Schwarz J, et al. N of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ 1994; 309: 1041-5
40. Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients. BMJ 1995; 310: 817-8
41. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241-9
42. 2 blockers: The ostrich phenomenon!'. Arch Intern Med 1993; 153: 2411-2
43. MacDonald TM, Morant SV, Robinson GC, et al. Risk of upper GI complications is constant with continuous NSAID use. Pharmacoepidemiol Drug Saf 1995; 4: S47
44. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995; 49: 33-5
45. Russell AL. Prescribing NSAIDs for elderly people. Can Med Assoc J 1994; 151: 1235-6
46. Airaksinen O, Venalainen J, Pietilainen T. Ketoprofen 2.5% gel versus placebo gel in the treatment of acute soft tissue injuries. Int J Clin Pharmacol Ther Toxicol 1993; 31: 561-3
47. Noret A, Roty V, Allington N, et al. Ketoprofen gel as topical treatment for sporting injuries. Acta Ther 1987; 13: 367-77
48. McLatchie GR, McDonald M. Soft tissue trauma: a randomised controlled trial of the topical application of felbinac, a new NSAID. Br J Clin Pract 1989; 43: 277-80
49. Kockelbergh M, Verspeelt P, Caloine R, et al. Local anti-inflammatory treatment with a ketoprofen gel: recent clinical data. Med Phys 1985; 8: 205-13
50. Schimek J, Hilken K, Vogtle-Junkert U. Topical anti-rheumatic treatment alone: an alternative to oral medication? Therapiewoche 1991; 41: 1075-80
51. Hosie GAC. The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. Br J Clin Res 1993; 4: 5-17
52. Goyan JE. Withdrawal of a drug from the market: what should the prescriber do? JAMA 1993; 270: 1976-7
53. Ross-Degnan D, Soumerai SB, Fortess EE, et al. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA 1993; 270: 1937-42
54. Editorial. Benoxaprofen. BMJ 1982; 285: 259-60
55. White S. Topical non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory musculoskeletal disorders. Prostaglandins Leukot Essent Fatty Acids 1991; 43: 209-22
56. Newbery R, Shuttleworth P, Rapier C. A multicentre post-marketing surveillance study to evaluate the safety and efficacy of felbinac 3% gel in the treatment of musculoskeletal disorders in general practice. Eur J Clin Res 1992; 3: 139-50
57. Baixauli F, Ingles F, Alcantara P, et al. Percutaneous treatment of acute soft tissue lesions with naproxen gel and ketoprofen gel. J Int Med Res 1990; 18: 372-8
58. Wood SM, Coulson R. Adverse drug reactions on-line information tracking (ADROIT). Pharm Med 1993; 7: 203-13
59. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and hospitalisation for upper gastrointestinal bleeding and perforation. BMJ 1995; 311: 22-6
60. O'Callaghan CA, Andrews PA, Ogg CS. Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ 1994; 308: 110-1
61. Fernando AHN, Thomas S, Temple RM, et al. Renal failure after topical use of NSAIDs [letter]. BMJ 1994; 308: 533
62. Committee on Safety of Medicines. Felbinac (Traxam) and bronchospasm. Curr Probl 1989; 27
63. Lawson DH. The yellow card: mark II. BMJ 1990; 301: 1234
64. Inman WHW. Yellow cards and green forms. Practitioner 1983; 227: 1443-9
65. Griffin JP. The yellow card: mark II [letter]. BMJ 1991; 302: 50
66. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Phys Lond 1995; 29: 41-9
67. Nolan L, O'Malley K. Adverse drug reactions in the elderly. Br J Hosp Med 1989; 41: 447-55
68. Beard K. Special considerations in the assessment of adverse drug reactions in the elderly. Pharm Med 1991; 5: 37-48
69. Robertson WH. The problem of patient compliance. Am J Obstet Gynecol 1985; 152: 948-52
70. The SAMM guidelines: guidelines for company-sponsored assessment of marketed medicines [editorial]. Pharmacoepidemiol Drug Saf 1994; 3: 1-6